Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well dasatinib works in treating patients with head and neck
cancer that has come back or spread to other areas of the body. Dasatinib may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth.